Does Acyclovir Prevent or Promote Cancer?
Acyclovir, an antiviral drug targeting herpes viruses like HSV and VZV, shows no direct promotion of cancer development. Lab studies indicate it inhibits proliferation in some cancer cell lines, such as cervical and nasopharyngeal carcinoma cells, by blocking viral replication and inducing apoptosis.[1][2] Population data from over 3,000 users found no increased cancer risk compared to non-users, with standardized incidence ratios near 1.0 across sites like lung (0.96) and prostate (1.02).[3]
Link to Viruses That Cause Cancer
Herpes viruses acyclovir treats do not directly cause cancer in humans, unlike EBV or HPV. Acyclovir curbs these viruses' activity, potentially reducing inflammation or latency that could indirectly support tumor growth in co-infected patients. No clinical trials confirm cancer risk reduction from routine acyclovir use.[4]
Lab Evidence on Cancer Cells
In vitro, acyclovir halts cell cycle progression in HSV-infected cancer models (e.g., HeLa cells) at G1/S phase and boosts p53-mediated death. Concentrations of 20-160 μg/mL suppress nasopharyngeal carcinoma growth by 50-80% via caspase activation.[2][5] These effects are dose-dependent and stronger against virus-positive cells, but human relevance remains unproven beyond antivirals' role.
Long-Term Safety in Cancer Risk Studies
A Danish cohort tracked 3,439 acyclovir users (1995-2007) for 10+ years against 17,181 controls. No excess cancers emerged; ratios stayed below 1.2 for most types, including skin (1.12) and lymphoma (1.32, not significant). Chronic use in immunocompromised patients showed similar neutrality.[3][6]
Potential Risks or Interactions in Cancer Patients
Acyclovir does not accelerate cancer but may interact with chemotherapy—e.g., nephrotoxicity with cisplatin. Rare mutagenesis in bacterial assays raised early flags, but mammalian tests were negative, and no carcinogenicity appeared in rodent studies up to 450 mg/kg/day.[7] Oncologists use it safely for herpes flares in cancer patients.
[1] PubMed: Acyclovir inhibits proliferation of cervical cancer cells
[2] PubMed: Antitumor effects on nasopharyngeal carcinoma
[3] PubMed: Cancer risk in acyclovir users (Danish cohort)
[4] CDC: Viruses and cancer overview
[5] Journal of Medical Virology: Cell cycle arrest by acyclovir
[6] British Journal of Clinical Pharmacology: Long-term cohort safety
[7] FDA Label: Zovirax (acyclovir) safety data